2120. Deputy Ken O'Flynn asked the Minister for Health whether her Department has issued guidance to ensure that health technology assessments of medicines intended to prevent or reduce the long-term incidence of chronic diseases, including type 2 diabetes or cardiovascular disease, appropriately account for long-term health outcomes and downstream health system savings; and if she will make a statement on the matter…
Topics / Medicinal Products
A subject heading for parliamentary questionsMedicinal Products
1,233 questions from 132 TDs, between 22 January 2025 and 22 October 2026.
1,233
questions
1,229 written, 4 oral
132
TDs have asked
11
parties and groups
Independents counted together
4
departments asked
Questions per month
The record holds no questions for August, when the Dáil does not sit.
Jan 2025Oct 2026
Show as a table
| Month | Questions |
|---|---|
| January 2025 | 17 |
| February 2025 | 66 |
| March 2025 | 28 |
| April 2025 | 35 |
| May 2025 | 43 |
| June 2025 | 58 |
| July 2025 | 56 |
| August 2025 | 0 |
| September 2025 | 36 |
| October 2025 | 38 |
| November 2025 | 58 |
| December 2025 | 27 |
| January 2026 | 18 |
| February 2026 | 70 |
| March 2026 | 142 |
| April 2026 | 87 |
| May 2026 | 156 |
| June 2026 | 127 |
| July 2026 | 82 |
| August 2026 | 0 |
| September 2026 | 62 |
| October 2026 | 27 |
Who asks, by party
The party each TD belonged to on the day, in alphabetical order. Parties differ a lot in size, and members of the Government answer questions rather than ask them, so this shows who raised it, not how much a party cares about it.
The TDs who asked most
Members of the Government answer questions rather than ask them. Each question counts once.
-
196
-
75
-
43
-
42
-
39
-
26
-
26
-
26
Asked of
Debated under the same heading
Debates whose official heading is exactly these words.
The questions
2121. Deputy Ken O'Flynn asked the Minister for Health what oversight role her Department exercises in relation to the methodological frameworks used by the National Centre for Pharmacoeconomics when conducting health technology assessments that inform reimbursement decisions by the Health Service Executive; and if she will make a statement on the matter. [20313/26]
2122. Deputy Ken O'Flynn asked the Minister for Health whether her Department has reviewed whether the health technology assessment methodology applied in Ireland is aligned with that used by comparable agencies internationally, including NICE in the United Kingdom, CADTH in Canada, or PBAC in Australia, particularly regarding the time horizons applied in cost-effectiveness modelling for preventive medicines; and if …
2123. Deputy Ken O'Flynn asked the Minister for Health whether her Department has undertaken any review of whether the methodological assumptions applied in health technology assessments used in Ireland may disadvantage medicines intended to prevent long-term chronic illness by applying short-term modelling horizons; and if she will make a statement on the matter. [20315/26]
2124. Deputy Ken O'Flynn asked the Minister for Health whether her Department intends to establish a national policy framework or guidance governing the methodological standards used in health technology assessments for medicines seeking reimbursement by the Health Service Executive, including standards relating to modelling time horizons for chronic disease prevention therapies; and if she will make a statement on t…
2177. Deputy Erin McGreehan asked the Minister for Health the specific steps the HSE is taking to ensure that the time critical and progressive nature of Friedreich's Ataxia is fully recognised and acted upon during the ongoing price and reimbursement negotiations for skyclarys, given the significant risk of irreversible decline for patients during prolonged delays. [20488/26]
2178. Deputy Erin McGreehan asked the Minister for Health the way in which the commitments outlined in the National Rare Disease Strategy 2025-2030 particularly those relating to timely access to innovative therapies are being applied in the case of skyclarys. [20489/26]
2179. Deputy Erin McGreehan asked the Minister for Health the way in which the 180 day decision timeline set out in the 2026 IPHA Framework Agreement is being implemented in practice for rare disease medicines; and the reason this timeline has not been met in the case of skyclarys for Friedreich's Ataxia patients. [20490/26]
2180. Deputy Erin McGreehan asked the Minister for Health whether her Department or the HSE has considered establishing an Early Access Programme for skyclarys, in light of the progressive and time sensitive nature of Friedreich's Ataxia, so that patients can access the treatment while reimbursement negotiations are ongoing. [20491/26]
2199. Deputy Maeve O'Connell asked the Minister for Health the position regarding the current reimbursement process for Omaveloxolone, considering the time-sensitive nature of the condition for those with Friedreich's ataxia; and if she will make a statement on the matter. [20597/26]
2219. Deputy Niall Collins asked the Minister for Health if she will ensure that the HSE prioritises a conclusion to the Skyclarys reimbursement negotiations, given that it is the only available treatment for a progressive disease Friedreich's Ataxia (FA), which currently can be classed as having an ‘unmet need’, as outlined in the National Rare Disease Strategy 2025 – 2030; whether she believes the current delay ali…
2221. Deputy Aengus Ó Snodaigh asked the Minister for Health the reason access to Friedreich's Ataxia is not available on the medical card or licenced for the drug reimbursement scheme for patients in the State; and if she will make a statement on the matter. [20816/26]
2225. Deputy Cathal Crowe asked the Minister for Health the reason the HSE no longer provides funding for Novofine autocover needles; whether an alternative product will be considered for funding (details supplied); and if she will make a statement on the matter. [20860/26]
22. Deputy Peter Roche asked the Minister for Health if her Department has considered introducing an early access scheme for people living with rare diseases to access EMA-approved orphan medicines; if such an early access scheme will include orphan medicines products licensed for non-oncology conditions; and if she will make a statement on the matter. [17621/26]
35. Deputy Pádraig O'Sullivan asked the Minister for Health if she will provide an appraisal of the work that has been carried out on a review of the drugs reimbursement scheme and the creation of an early access scheme as per Programme for Government commitments; and if she will make a statement on the matter. [17474/26]
60. Deputy Peter Roche asked the Minister for Health when she intends to commence a review of the reimbursement process, as committed to in the Programme for Government; whether such a review will specifically include the way in which orphan medicines are assessed and reimbursed; and if she will make a statement on the matter. [17622/26]
75. Deputy Catherine Ardagh asked the Minister for Health her plans to expand access to weight loss medications given the health and societal costs of obesity; and if she will make a statement on the matter. [17500/26]
101. Deputy Aindrias Moynihan asked the Minister for Health the up-to-date position on a medication (details supplied) being available on the drugs payment scheme; and if she will make a statement on the matter. [17677/26]
119. Deputy Catherine Ardagh asked the Minister for Health her plans to review current regulations regarding the prescription of melatonin; and if she will make a statement on the matter. [17499/26]
120. Deputy Pádraig Rice asked the Minister for Health to provide an update on the delivery of the programme for Government commitment to continue to extend access to free contraception; the work carried out to date; the timeline she is working towards in expanding the scheme; and if she will make a statement on the matter. [17723/26]
525. Deputy Conor Sheehan asked the Minister for Health the specific steps being taken to ensure the HSE considers the time-critical nature of Friedreich’s ataxia during the current price negotiations for Skyclarys, the only drug approved for treatment of this condition, given the 570 days since the application for use was lodged and the rapid progression of the disease in sufferers; and if she will make a statement …
526. Deputy Conor Sheehan asked the Minister for Health the way in which the commitments in the National Rare Disease Strategy 2025 – 2030 are being applied to the approval process for the drug Skyclarys used to treat Friedrich's ataxia to prevent further delays in addressing the unmet need of sufferers; and if she will make a statement on the matter. [17918/26]
527. Deputy Conor Sheehan asked the Minister for Health the way in which the 2026 IPHA Framework Agreement on access to new and innovative medicines which aims for a 180-day decision timeline is being applied to the drug Skyclarys used to treat Friedrich's ataxia to prevent further delays in addressing the unmet need of sufferers; and if she will make a statement on the matter. [17919/26]
538. Deputy Alan Kelly asked the Minister for Health if she will intervene to ensure that the HSE prioritises a conclusion to the Skyclarys reimbursement negotiations, given that it is the only available treatment for this progressive disease, which currently can be classed as having an ‘unmet need’ as outlined in the National Rare Disease Strategy 2025 – 2030; and if she will make a statement on the matter. [17958/2…
539. Deputy Alan Kelly asked the Minister for Health her views on whether the current delay regarding the Skyclarys reimbursement negotiations aligns with the "equitable access" promised in the newly launched National Rare Disease Strategy 2025-2030; and if she will make a statement on the matter. [17959/26]